Related Experiment Video

Updated: Feb 26, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.9K

Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents

Jung-Eun Park1, David Hymel2, Terrence R Burke2

  • 1Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

F1000Research
|July 20, 2017
PubMed

Insights

New anti-cancer drugs targeting polo-like kinase 1 (Plk1) aim to reduce side effects and improve tumor specificity. This research reviews current Plk1 inhibitor development and future therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Microtubule-directed agents are effective anti-cancer therapeutics but cause significant side effects.
  • Targeting mitotic proteins aims to develop safer and more specific anti-cancer drugs.
  • Polo-like kinase 1 (Plk1) is a key mitotic protein and an attractive target for anti-cancer drug development.

Purpose of the Study:

  • To review the current status of anti-Plk1 agent development.
  • To discuss future strategies for designing more efficacious Plk1 therapeutics.
  • To explore novel anti-mitotic agents with reduced side effects and enhanced tumor specificity.

Main Methods:

  • Review of existing literature on Plk1 inhibitors.
  • Analysis of clinical trial data for anti-Plk1 agents.
  • Discussion of future drug design strategies for Plk1 therapeutics.

Main Results:

  • Numerous anti-Plk1 agents have been developed.
  • Several Plk1 inhibitors are currently in clinical trials.
  • Ongoing research focuses on improving efficacy and reducing side effects.

Conclusions:

  • Plk1 remains a highly promising target for anti-cancer drug discovery.
  • Further research is needed to optimize Plk1 inhibitors for clinical use.
  • Future strategies will focus on enhanced tumor specificity and reduced toxicity.
Keywords:
Plk1anti-Plk1 agentsanti-cancer therapeuticsanti-mitotic agentsmitotic targetspolo-like kinase 1

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.3K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.6K